First Eagle Investment Management LLC increased its position in shares of Becton, Dickinson and Company (NYSE:BDX – Free Report) by 15.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 13,815,335 shares of the medical instruments supplier’s stock after purchasing an additional 1,887,224 shares during the quarter. Becton, Dickinson and Company accounts for approximately 2.3% of First Eagle Investment Management LLC’s investment portfolio, making the stock its 12th largest position. First Eagle Investment Management LLC owned 0.05% of Becton, Dickinson and Company worth $2,090,675,000 at the end of the most recent reporting period.
Other large investors have also recently bought and sold shares of the company. Imprint Wealth LLC acquired a new stake in shares of Becton, Dickinson and Company during the 3rd quarter worth approximately $25,000. SHP Wealth Management bought a new position in Becton, Dickinson and Company in the fourth quarter valued at approximately $26,000. Prosperity Bancshares Inc acquired a new position in Becton, Dickinson and Company during the fourth quarter valued at approximately $29,000. Meeder Asset Management Inc. lifted its stake in Becton, Dickinson and Company by 152.2% during the first quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock worth $27,000 after purchasing an additional 102 shares during the last quarter. Finally, Tucker Asset Management LLC bought a new stake in Becton, Dickinson and Company during the fourth quarter worth $34,000. 86.97% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
BDX has been the topic of several recent analyst reports. Royal Bank Of Canada lifted their price target on Becton, Dickinson and Company from $180.00 to $190.00 and gave the company a “sector perform” rating in a research note on Thursday, August 13th. Weiss Ratings restated a “sell (d+)” rating on shares of Becton, Dickinson and Company in a research report on Friday, August 7th. TD Cowen raised their price objective on Becton, Dickinson and Company from $163.00 to $182.00 and gave the company a “hold” rating in a research note on Wednesday, August 5th. Jefferies Financial Group reissued a “buy” rating and set a $210.00 target price on shares of Becton, Dickinson and Company in a research note on Thursday, August 6th. Finally, The Goldman Sachs Group dropped their target price on shares of Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating for the company in a report on Wednesday, May 27th. Eight investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Becton, Dickinson and Company currently has an average rating of “Hold” and a consensus price target of $187.67.
Insider Transactions at Becton, Dickinson and Company
In other Becton, Dickinson and Company news, CEO Thomas E. Polen, Jr. sold 4,152 shares of the company’s stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $185.00, for a total value of $768,120.00. Following the completion of the transaction, the chief executive officer directly owned 110,163 shares in the company, valued at approximately $20,380,155. This represents a 3.63% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Garrison sold 1,100 shares of the firm’s stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total transaction of $160,226.00. Following the transaction, the executive vice president directly owned 13,172 shares of the company’s stock, valued at $1,918,633.52. The trade was a 7.71% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 9,105 shares of company stock valued at $1,590,208. 0.40% of the stock is currently owned by company insiders.
Becton, Dickinson and Company Stock Up 0.0%
Shares of BDX opened at $184.78 on Monday. Becton, Dickinson and Company has a 52 week low of $127.59 and a 52 week high of $193.07. The stock has a market capitalization of $50.91 billion, a price-to-earnings ratio of 55.66, a PEG ratio of 13.02 and a beta of 0.21. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87. The stock has a fifty day moving average of $170.05 and a 200-day moving average of $160.58.
Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, topping analysts’ consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%.The business had revenue of $4.98 billion for the quarter, compared to analyst estimates of $4.89 billion. During the same quarter in the previous year, the company posted $3.68 EPS. Becton, Dickinson and Company’s quarterly revenue was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, sell-side analysts anticipate that Becton, Dickinson and Company will post 12.67 earnings per share for the current fiscal year.
Becton, Dickinson and Company Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be issued a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a dividend yield of 2.3%. The ex-dividend date is Wednesday, September 9th. Becton, Dickinson and Company’s payout ratio is 126.51%.
Becton, Dickinson and Company Company Profile
Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.
BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.
Featured Stories
- Five stocks we like better than Becton, Dickinson and Company
- AI Token Costs Are Changing the Hardware vs. Software Debate
- 3 ETFs That Could Move as Rate Expectations Shift
- 3 Stocks With September Catalysts Investors Shouldn’t Ignore
- Ollie’s Bargain Outlet Stock Falls on Weak Comps Despite Margin Gains
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX – Free Report).
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.
